Subject(s)
DNA, Viral/analysis , Nucleic Acid Hybridization , Papillomaviridae/isolation & purification , Papillomavirus Infections/diagnosis , Tumor Virus Infections/diagnosis , Female , Humans , Nucleic Acid Hybridization/methods , Papillomaviridae/genetics , Papillomavirus Infections/virology , Polymerase Chain Reaction , Tumor Virus Infections/virologyABSTRACT
BACKGROUND AND OBJECTIVE: Very diverse treatment recommendations exist in the literature on HPV lesions of the urethra. There are no treatment guidelines from the specialist societies. Both these factors have led to a very wide spectrum of heterogeneous treatment strategies in hospitals and medical practices of various specialties. Primary and secondary treatment of urethral condylomata by practitioners as well as a specialized HPV center was evaluated. PATIENTS/METHODS: One hundred and five patients with condylomata of the urethra were studied. Most had been previously treated, often several times, by a variety of specialists. We treated all regardless of prior treatment status with laser therapy. RESULTS: A high percentage of patients treated with different methods in medical practices but also at our high-technology center sometimes showed serious treatment complications and numerous recurrences. Most established methods of treatment for condylomata on the external genitalia are not necessarily applicable to the urethra. CONCLUSIONS: About 20% of urethral condylomata can only be reached by endoscopy. Co-existing urethral malformations as well as complications of therapy are reasons for early cooperation with the urologist or HPV center.
Subject(s)
Condylomata Acuminata/surgery , Urethral Neoplasms/surgery , Adult , Condylomata Acuminata/diagnosis , Condylomata Acuminata/pathology , Diagnosis, Differential , Female , Humans , Laser Therapy , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Postoperative Complications/diagnosis , Postoperative Complications/pathology , Postoperative Complications/surgery , Reoperation , Urethra/pathology , Urethra/surgery , Urethral Neoplasms/diagnosis , Urethral Neoplasms/pathologyABSTRACT
A randomized controlled study has been carried out in order to check the activity of caerulein in the treatment of biliary and renal colic. In 88% out of 107 patients caerulein, 1 ng/kg IV, relieved biliary colic and had no side effects. To elucidate the mechanism of action of the peptide, 22 cholecystectomized patients, showing a dilation of the common bile duct (CBD), were submitted to caerulein treatment under echo-control. Reduction of CBD caliber was noticed when the dilatation was due to functional obstruction, whereas an organic obstruction of the terminal tract of CBD was found in the non-responding patients. Caerulein appears to be an effective agent in relieving biliary colic through a relaxation of Oddi's sphincter, and may be used in ultrasound differential diagnostics of terminal bile duct obstruction. Caerulein, 75 ng/kg intramuscularly, relieved renal colic in 75% of the examined patients; it is suggested that the effect of caerulein in this syndrome is due to central analgesic action.
